secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-07-13T11:39:07+00:00
Accession:  0001104659-26-082875
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience reports ~$244.2M cash; plans additional Phase 3 trial for ALTO-207
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and restricted cash of ~$244.2M as of June 30, 2026 (unaudited).
- Company intends to accelerate ALTO-207 development, including an additional Phase 3 monotherapy trial for treatment-resistant depression.
- No other financial results or guidance provided in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/0001104659-26-082875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/tm2620297d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer